No Data
No Data
No Data
No Data
No Data
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology's international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (NASDAQ:VSTM), a
BusinesswireApr 19 04:05
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)
TipRanksApr 16 18:00
VS-6766 Drug Research 2024: Developed by Verastem Oncology, An RAF/MEK Clamp That Induces Inactive Complexes of MEK With ARAF, BRAF, and CRAF - Market Size, Forecast, and Emerging Insights 2019-2032
Yahoo FinanceApr 16 17:05
Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)
TipRanksApr 12 19:00
Verastem Releases Updated Corporate Presentation for Investors
TipRanksApr 10 05:22
Verastem Oncology Partner GenFleet Therapeutics Unveils Latest Research Findings Of GFH375 At AACR Annual Meeting
Verastem Oncology Partner GenFleet Therapeutics Unveils Latest Research Findings Of GFH375 At AACR Annual Meeting
BenzingaApr 9 19:16
No Data
No Data